Einrichtung

Center for Human Genetics and Prevention Stuttgart

Reinsburgstr. 13
70178 Stuttgart
Germany

Leiter bzw. Ansprechpartner der Einrichtung

Dr. med. Robert Hering

Kategorisierung

  •  Genetische Beratung
  •  Zytogenetik
  •  Molekulare Zytogenetik
  •  Molekulargenetik
  •  Tumorzytogenetik

Andere Einstellungen

  •  Subtelomer-Tests
  •  Pränataler Schnelltest

Hauptkontakt des Instituts

Molekulargenetik

Genetische Beratung

Allgemeine Anmeldung, Sekretariat

Diagnosen

Gen Krankheit OMIM Methode
CYP21A2
ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY201910, 202110
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
AR
ANDROGEN INSENSITIVITY SYNDROME; AIS300068
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
PTCH
PTCH2
SUFU
BASAL CELL NEVUS SYNDROME; BCNS109400
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
ERCC6
ERCC8
COCKAYNE SYNDROME TYPE A, ~B216400, 133540
  • Sanger-Sequenzierung
CFTR
CYSTIC FIBROSIS; CF219700
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
GJB2
GJB6
DEAFNESS, NEUROSENSORY, AUTOSOMAL RECESSIVE 1; DFNB1220290
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • Deletionsscreening
FABRY DISEASE301500
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
CDH1
GASTRIC CANCER137215
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
HRPT2
HYPERPARATHYROIDISM 2145001
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
FLG
Ichtyosis146700
  • Sanger-Sequenzierung
IKBKG
INCONTINENTIA PIGMENTI; IP308300
  • Sanger-Sequenzierung
BMPR1A
ENG
MADH4
Juvenile Polyposis / Hereditary Hemorrhagic Telangiectasia Syndrome175050, 615506, 174900
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
RNASET2
LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY612951
  • Sanger-Sequenzierung
CHECK2
p53
LI-FRAUMENI SYNDROME 1; LFS1151623
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
KCNH2
KCNQ1
SCN5A
Long QT Syndrome192500, 611820, 600919, 6
  • Sanger-Sequenzierung
CDKN2A
MELANOMA-PANCREATIC CANCER SYNDROME606719
  • Sanger-Sequenzierung
FH
Multiple cutaneous and uterine myomata 1150800
  • Sanger-Sequenzierung
CDKN1B
MULTIPLE ENDOCRINE NEOPLASIA TYPE IV610755
  • Sanger-Sequenzierung
MEN1
MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1131100
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
NF1
NEUROFIBROMATOSIS, TYPE I; NF1162200
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
NF2
NEUROFIBROMATOSIS, TYPE II; NF2101000
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
ACVRL1
OSLER-RENDU-WEBER SYNDROME 2; ORW2600376
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
KRT1
KRT9
PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK144200
  • Sanger-Sequenzierung
SDHC
PARAGANGLIOMAS 3; PGL3605373
  • Sanger-Sequenzierung
STK11
PEUTZ-JEGHERS SYNDROME; PJS175200
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
F5
MTHFR
PROS1
PLASMINOGEN ACTIVATOR INHIBITOR 1; PAI1173360
  • Sanger-Sequenzierung
JAK2
Polycythämia vera263300
  • Sanger-Sequenzierung
PROC
PROTEIN C DEFICIENCY, CONGENITAL THROMBOTIC DISEASE DUE TO176860
  • Sanger-Sequenzierung
PROS1
PROTEIN S, ALPHA; PROS1176880
  • Sanger-Sequenzierung
SRD5A2
PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH264600
  • Sanger-Sequenzierung
MET
RENAL CELL CARCINOMA, PAPILLARY605074
  • Sanger-Sequenzierung
RETINOBLASTOMA; RB1180200
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
ENG
TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER; HHT187300
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
TSC2
TSC2 GENE; TSC2191092
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
TSC1
TSC2
TUBEROUS SCLEROSIS; TS191100
  • Sanger-Sequenzierung
  • MLPA (Multiple Ligation-dependent Probe Amplification
BAP1
Tumor predisposition syndrome (TPDS)614327
  • Sanger-Sequenzierung
IRF6
VAN DER WOUDE SYNDROME; VWS119300, 606713
  • Sanger-Sequenzierung
ATP7B
WILSON DISEASE277900
  • Sanger-Sequenzierung

Panels

Gen Name Kategorie Schlagworte/Indikation
APC
BMPR1A
ENG
MADH4
MUTYH
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben
MLH1
MSH2
MSH6
PIK3CA
PMS2
... (6)
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben
AKT1
PIK3CA
PTEN
SDHB
SDHD
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben
BRCA1
BRCA2
CDH1
CHECK2
p53
... (9)
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben
ACTA2
FBN1
MYH11
MYLK
TGFBR1
... (6)
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben
RET
SDHB
SDHC
SDHD
VHL
Imported from Diagnostics
Spezifikation
  • Molecular Genetic
Methode
  • MLPA (Multiple Ligation-dependent Probe Amplification
  • DNA-Sequenzierung
Größe
keine Angaben

Ringversuche

Ringversuch Kategorisierung Organisator Jahr